“In the U.S., we are on track to submit for FDA approval for Hugo with urology indications by the end of next month.”

In context

“int impact on our surgical performance. We expect this to resolve as we start fiscal ‘26. Apart from this distributor dynamic, our U.S. hospital customer purchasing, direct from us and through distributors, has been stable. And while we continue to see market and competitive pressures in our stapling franchise, we're offsetting this by winning share with our LigaSure Advanced Energy Products globally, and by driving strong, high-single-digit growth in emerging markets. With our Hugo Soft-Tissue robotic platform, we're approaching some important milestones, including entering the U.S. market, expanding indications, adding features, and enhancing system performance. In international markets, utilization continues to increase, and we've more than doubled Hugo procedure volume year-over-year. In the U.S., we are on track to submit for FDA approval for Hugo with urology indications by the end of next month. I also have some new information to share with you today. We have finished enrollment in our hernia and benign GYN studies. Further, we recently received FDA approval to initiate our GYN oncology ID study and are actively moving that forward. We're also making progress adding features and instrumentation. We just completed our first cases using our ICG fluorescent imaging, and we expect to add our LigaSure Vessel Sealing technology to Hugo later this calendar year. So in total, we are confident in our path forward. Hugo will be a growth driver for our surgical business and fiscal ‘26 and a meaningful growth driver for Medtronic in the mid-term. Finally in diabetes we had our fifth quarter in a row of double-digit growth. We printed 10% growth on top of 10% growth in the prior year. Our gr”